



Christmas is approaching after an exciting and intense autumn. Unfortunately, no snow in sight here in Uppsala, but we still look forward to some cozy days with family and friends waiting for Santa Claus. At this moment, I would like to take this opportunity to summarize a very active 2019 for AroCell.

We launched a new website in January to more clearly communicate the benefits of measuring TK1 in cancer patients. We have also been more active in social media and we note that more people are following us, and more people are interested in our company. During the autumn, we strengthened our cash and secured the company's finances through a directed and a rights issue. This will keep us afloat until we receive an FDA clearance of our product AroCell TK 210 ELISA for the US market. In connection with this, we have strengthened our organization by associating Peter Löwendahl with AroCell as Regulatory Director. Additional two strategic recruitments are underway to strengthen important parts of the company.

There has been high activity in clinical trials. We have presented data from two clinical studies, With the PROMIX data showing how TK1 can be used as a response biomarker in chemo treated breast cancer patients. We have initiated collaborations with Tampere University on prostate cancer and Dana Farber for patients treated with CDK 4/6 inhibitors. We have strengthen our IP position with two new patent approvals during the year.

By signing agreements with Gongyingshi for China, InventioLife for India and DiaPharma for the US and Canada we have built up a network of distributors. This, together with existing distributors, gives full coverage in our priority markets, North America, Asia and Europe. In addition, we have established cooperation with a contract lab, Corgenix in the USA, which performs TK1 analyzes with our TK 210 ELISA.

Yes, it has really been an active year for AroCell and I can proudly and confidently say that 2019 has been a big leap forward for AroCell. A leap that has only been possible through dedicated employees who collaborated effectively to achieve the greatest possible development of AroCell in 2019, Thank you!

I would now like to take this opportunity to thank all shareholders, stakeholders and partners for good collaboration and cooperation. Now, soon Christmas is coming and for me it's time to wish you a Merry Christmas and a Happy New Year.

We look forward to a very exciting 2020!
Michael Brobjer, CEO of AroCell

aroCell

